Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2307489 | 1.00 | ESR1 (0.36) | ESR1ESR2 | |
| SCHEMBL2934411 | 0.98 | ESR1 (0.36) | ESR1ESR2 | |
| SCHEMBL8665314 | 0.82 | — | — | |
| SCHEMBL538153 | 0.79 | — | — | |
| SCHEMBL10500778 | 0.79 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL4729293 | 0.79 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL7551581 | 0.79 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL9578948 | 0.79 | CES1 (0.47) | ESR1ESR2 | |
| SCHEMBL7593649 | 0.79 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL19578784 | 0.79 | CES1 (0.47) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11465990-B2 | Heterocyclic antiestrogens | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2022-10-11 | — | — | US | disclosed |
| CN-108699021-B | Heterocyclic antiestrogens | 太阳医药高级研究有限公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-4043438-A1 | NOVEL HETEROCYCLIC ANTIESTROGENS | Sun Pharma Advanced Research Company Limited (IN) | 2022-08-17 | — | — | EP | disclosed |
| EP-3368519-B1 | NOVEL HETEROCYCLIC ANTIESTROGENS | SUN PHARMA ADVANCED RES CO LTD (IN) | 2022-04-06 | — | — | EP | disclosed |
| EP-3932922-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | ShanghaiTech University (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-10865199-B2 | Heterocyclic antiestrogens | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2020-12-15 | — | — | US | disclosed |
| US-20180354936-A1 | NOVEL HETEROCYCLIC ANTIESTROGENS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2018-12-13 | — | — | US | disclosed |
| EP-3368519-A1 | NOVEL HETEROCYCLIC ANTIESTROGENS | Sun Pharma Advanced Research Company Limited (IN) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017072792-A1 | NOVEL HETEROCYCLIC ANTIESTROGENS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2017-05-04 | — | — | WO | disclosed |
| EP-1436256-B1 | PREPARATION PROCESS OF SOME HALOGENO-SUBSTITUTED MONOSULFIDES AND THEIR HYDROXY-MONOSULFIDE OR ISOTHIOURONIUM BROMIDE EQUIVALENTS AS INTERMEDIATES | ASTRAZENECA AB (SE) | 2011-08-10 | — | — | EP | disclosed |
| US-7947667-B2 | Aromatization; hydrolysis; deblocking, deprotecting; oxidation; for production of fulvestrant | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| WO-2008044033-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-04-17 | — | — | WO | disclosed |
| EP-0642529-B1 | 11BETA-SUBSTITUTED 14,17-ETHANOESTRATRIENES, PROCESS FOR PREPARING THESE COMPOUNDS AND THEIR USE FOR PREPARING MEDICAMENTS | SCHERING AG (DE) | 1996-12-11 | — | — | EP | disclosed |
| US-5502046-A | 11β-substituted 14,17-ethanoestratrienes, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-03-26 | — | — | US | disclosed |
| EP-0642529-A1 | 11-g(b)-SUBSTITUTED 14,17-ETHANOESTRATRIENES, PROCESS FOR PREPARING THESE COMPOUNDS AND THEIR USE FOR PREPARING MEDICAMENTS. | SCHERING AG (DE) | 1995-03-15 | — | — | EP | disclosed |
| EP-0546591-A2 | 11-beta-substituted 14,17-ethanoestratrienes, process for their production and their use in the preparation of medicines | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-06-16 | — | — | EP | disclosed |
| WO-1993006124-A1 | 11β-SUBSTITUTED 14,17-ETHANOESTRATRIENES, PROCESS FOR PREPARING THESE COMPOUNDS AND THEIR USE FOR PREPARING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354936-A1 | NOVEL HETEROCYCLIC ANTIESTROGENS | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885 |
| US-11465990-B2 | Heterocyclic antiestrogens | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885 |
| US-10865199-B2 | Heterocyclic antiestrogens | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.